Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Agilon Health (AGL) EBITDA Margin (2020 - 2025)

Agilon Health (AGL) has disclosed EBITDA Margin for 6 consecutive years, with 12.99% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 541.0% year-over-year to 12.99%, compared with a TTM value of 7.78% through Dec 2025, down 299.0%, and an annual FY2025 reading of 7.78%, down 299.0% over the prior year.
  • EBITDA Margin was 12.99% for Q4 2025 at Agilon Health, down from 8.88% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 0.2% in Q1 2023 and bottomed at 59.68% in Q2 2021.
  • Average EBITDA Margin over 5 years is 9.0%, with a median of 5.81% recorded in 2022.
  • The sharpest move saw EBITDA Margin tumbled -5942bps in 2021, then soared 5663bps in 2022.
  • Year by year, EBITDA Margin stood at 17.02% in 2021, then increased by 16bps to 14.3% in 2022, then dropped by -8bps to 15.47% in 2023, then surged by 51bps to 7.57% in 2024, then crashed by -71bps to 12.99% in 2025.
  • Business Quant data shows EBITDA Margin for AGL at 12.99% in Q4 2025, 8.88% in Q3 2025, and 8.04% in Q2 2025.